LTGO · Latigo Biotherapeutics, Inc.
The latest filing states the doubt was alleviated.
“Accordingly, the prior substantial doubt about the Company's ability to continue as a going concern has been alleviated.”View the 10-Q filed Sep 3, 2026
Price & Indicators
The closing range uses available history since Aug 7, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LTGO
this stock
Latigo Biotherapeutics, Inc.
|
$1.53B | — | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$64.25B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LTGO | -4.9% | +26.3% | — | +4.6% | — |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -5.0% | +26.7% | — | +4.2% | — |